Rhumbline Advisers trimmed its holdings in shares of Blueprint Medicines (NASDAQ:BPMC) by 9.2% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 40,911 shares of the biotechnology company’s stock after selling 4,122 shares during the period. Rhumbline Advisers owned approximately 0.10% of Blueprint Medicines worth $3,085,000 as of its most recent filing with the Securities and Exchange Commission.
Other large investors have also bought and sold shares of the company. Zurcher Kantonalbank Zurich Cantonalbank raised its position in Blueprint Medicines by 57.3% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,866 shares of the biotechnology company’s stock valued at $141,000 after buying an additional 680 shares during the period. First Mercantile Trust Co. purchased a new position in Blueprint Medicines in the fourth quarter valued at about $183,000. Turner Investments LLC purchased a new position in Blueprint Medicines in the third quarter valued at about $209,000. Public Employees Retirement Association of Colorado purchased a new position in Blueprint Medicines in the fourth quarter valued at about $227,000. Finally, Great West Life Assurance Co. Can grew its stake in Blueprint Medicines by 53.6% in the third quarter. Great West Life Assurance Co. Can now owns 3,332 shares of the biotechnology company’s stock valued at $228,000 after purchasing an additional 1,163 shares in the last quarter. 97.79% of the stock is currently owned by hedge funds and other institutional investors.
In related news, Director Nicholas Lydon sold 25,000 shares of the stock in a transaction that occurred on Wednesday, February 28th. The stock was sold at an average price of $87.89, for a total transaction of $2,197,250.00. Following the completion of the sale, the director now owns 193,131 shares in the company, valued at approximately $16,974,283.59. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Daniel Lynch sold 17,500 shares of the stock in a transaction that occurred on Monday, February 12th. The shares were sold at an average price of $74.84, for a total value of $1,309,700.00. Following the sale, the director now owns 202,812 shares of the company’s stock, valued at approximately $15,178,450.08. The disclosure for this sale can be found here. In the last quarter, insiders have sold 89,567 shares of company stock valued at $7,651,106. 3.40% of the stock is currently owned by corporate insiders.
A number of brokerages have commented on BPMC. Cowen restated a “buy” rating on shares of Blueprint Medicines in a research note on Wednesday, February 21st. JMP Securities boosted their target price on Blueprint Medicines from $88.00 to $97.00 and gave the company an “outperform” rating in a research note on Monday, December 11th. BidaskClub downgraded Blueprint Medicines from a “strong-buy” rating to a “buy” rating in a research note on Thursday, March 29th. Zacks Investment Research upgraded Blueprint Medicines from a “hold” rating to a “buy” rating and set a $87.00 target price on the stock in a research note on Monday, January 8th. Finally, ValuEngine upgraded Blueprint Medicines from a “hold” rating to a “buy” rating in a research note on Monday, April 2nd. One equities research analyst has rated the stock with a sell rating and twelve have issued a buy rating to the stock. Blueprint Medicines has a consensus rating of “Buy” and a consensus target price of $84.20.
Shares of BPMC traded down $2.36 during trading hours on Friday, hitting $89.64. 325,856 shares of the company were exchanged, compared to its average volume of 345,212. The company has a market cap of $4,020.77, a PE ratio of -22.87 and a beta of 0.97. Blueprint Medicines has a 52 week low of $34.38 and a 52 week high of $109.00. The company has a debt-to-equity ratio of 0.02, a quick ratio of 15.98 and a current ratio of 15.98.
Blueprint Medicines (NASDAQ:BPMC) last released its quarterly earnings results on Wednesday, February 21st. The biotechnology company reported ($1.23) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.07) by ($0.16). The company had revenue of $1.63 million for the quarter, compared to the consensus estimate of $5.28 million. Blueprint Medicines had a negative return on equity of 38.79% and a negative net margin of 691.30%. The business’s revenue was down 78.8% compared to the same quarter last year. During the same quarter last year, the company posted ($0.75) EPS. research analysts predict that Blueprint Medicines will post -4.85 earnings per share for the current year.
TRADEMARK VIOLATION NOTICE: This article was first reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this article on another domain, it was copied illegally and reposted in violation of U.S. & international trademark and copyright laws. The correct version of this article can be read at https://www.dispatchtribunal.com/2018/04/07/rhumbline-advisers-cuts-holdings-in-blueprint-medicines-corp-bpmc.html.
Blueprint Medicines Profile
Blueprint Medicines Corporation, a biopharmaceutical company, develops drugs of small molecule kinase inhibitors that target genomic drivers in various cancers and a rare genetic disease. Its lead drug candidates include avapritinib, which is in Phase I clinical trials that targets KIT Exon 17 mutant proteins and PDGFRa D842V mutations, that are drivers of cancer and proliferative disorders, including gastrointestinal stromal tumors and systemic mastocytosis; and BLU-554, which is in Phase I clinical trials an orally available, potent, and irreversible inhibitor of the kinase FGFR4 that is activated in a defined subset of patients with hepatocellular carcinoma.
Receive News & Ratings for Blueprint Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Blueprint Medicines and related companies with MarketBeat.com's FREE daily email newsletter.